Optinose Announces Reporting Date for First Quarter 2024 Financial Results
10 mai 2024 14h56 HE
|
Optinose, Inc.
YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
CytoSorbents Reports First Quarter 2024 Results
09 mai 2024 16h17 HE
|
CytoSorbents
CytoSorbents Reports First Quarter 2024 Results
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
08 mai 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative...
Arbutus to Participate in Two Upcoming Investor Conferences
07 mai 2024 07h30 HE
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a...
BioNTech veröffentlicht Ergebnisse für das erste Quartal 2024 sowie Informationen zur Geschäftsentwicklung
06 mai 2024 06h45 HE
|
BioNTech SE
BioNTech ist auf einem gutem Weg, das Jahresziel von zehn oder mehr potenziell zulassungsrelevanten Studien in der Pipeline bis Ende 2024 zu erreichen: weitere Phase-3-Studie mit der Behandlung der...
BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
06 mai 2024 06h45 HE
|
BioNTech SE
Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating BNT323/DB-1303 in HR+ HER2-low...
MacroGenics Announces Date of First Quarter 2024 Financial Results Conference Call
03 mai 2024 07h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, May 03, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
02 mai 2024 07h30 HE
|
Arbutus Biopharma Corporation
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001...
MYR Group Inc. Announces First-Quarter 2024 Results
01 mai 2024 16h13 HE
|
MYR Group, Inc.
THORNTON, Colo., May 01, 2024 (GLOBE NEWSWIRE) -- MYR Group Inc. (“MYR”) (NASDAQ: MYRG), a holding company of leading specialty contractors serving the electric utility infrastructure, commercial...
FAT BRANDS INC. REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
01 mai 2024 16h05 HE
|
FAT Brands Inc.
Conference call and webcast today at 5:00 p.m. ET LOS ANGELES, May 01, 2024 (GLOBE NEWSWIRE) -- FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”) today...